{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T09:09:44Z","timestamp":1784538584618,"version":"3.55.0"},"reference-count":31,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_med-2026-1450_abs_001\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To compare the QoL of patients diagnosed with low- or favorable-intermediate-risk PCa after focal HDR brachytherapy and active surveillance. Our secondary objectives were to compare progression-free survival (PFS) between patients who underwent focal treatment and those who were actively surveilled and to assess early and late GU and GI adverse effects after the focal HDR brachytherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_med-2026-1450_abs_002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This prospective randomized controlled trial was conducted at the National Cancer Center located in Vilnius, Lithuania. The study was initiated after approval from the Vilnius Regional Biomedical Research Ethics Committee was obtained (Approval ID 2022\/6-1438-911). Twenty-seven patients were assigned to the AS group and 28 to the focal HDR\u00a0group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_med-2026-1450_abs_003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>During the median follow-up time of 14 and 17\u00a0months for AS and HDR groups, respectively, the QoL, evaluated by the EORTC QLQ-30 and PR25 instruments, showed no statistically significant differences in functional scores between the groups after baseline adjustment. Additionally, patients in the HDR group reported better urinary outcomes as measured by EORTC PR25 and IPSS scores at 6, 12, and 18\u00a0months. There were no statistically significant differences in erectile function between the groups as measured by the IIEF. Early toxicity was low (no Grade\u00a0\u22653 events), and only two cases (7.1 %) of Grade 2 GU toxicity were reported in the HDR group within the first 3\u00a0months, with one case persisting for 6\u00a0months. Late toxicity was not assessed during this interim follow-up. The HDR group demonstrated a non-significant trend toward better oncological outcomes, with fewer PSA-based recurrences and a higher mean PFS than the AS. At the time of last follow-up, 49\/55 (89\u202f%) patients were censored (22\/27 in the AS and 27\/28 in the HDR group).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_med-2026-1450_abs_004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>A current study shows comparable QoL and early toxicity results between AS and HDR groups. Any domain-level signals were below MCID and did not persist after baseline adjustment. Results of PFS are underpowered at this interim analysis due to short follow-up and high censoring, and should be considered hypothesis-generating only. However, as current results are only exploratory and insufficient to assess durable disease control or late toxicity, a longer follow-up, larger cohorts, and a multicenter approach are needed to provide definitive outcomes to demonstrate the benefit of focal brachytherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/med-2026-1450","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T08:57:44Z","timestamp":1784537864000},"source":"Crossref","is-referenced-by-count":0,"title":["Early outcomes after focal high-dose-rate brachytherapy in low- and favorable intermediate-risk prostate cancer: promising early results from a prospective randomized trial"],"prefix":"10.1515","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6457-4383","authenticated-orcid":false,"given":"Justinas","family":"Jonusas","sequence":"first","affiliation":[{"name":"Clinic of Hematology and Oncology , Institute of Clinical Medicine, Faculty of Medicine, Vilnius University , Vilnius , Lithuania"},{"name":"Laboratory of Cancer Epidemiology , National Cancer Institute , Vilnius , Lithuania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3874-2723","authenticated-orcid":false,"given":"Ausvydas","family":"Patasius","sequence":"additional","affiliation":[{"name":"Laboratory of Cancer Epidemiology , National Cancer Institute , Vilnius , Lithuania"},{"name":"Department of Public Health , Institute of Health Sciences, Faculty of Medicine, Vilnius University , Vilnius , Lithuania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mantas","family":"Trakymas","sequence":"additional","affiliation":[{"name":"Center of Diagnostic Oncology, National Cancer Center , Vilnius , Lithuania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3015-265X","authenticated-orcid":false,"given":"Kestutis","family":"Akelaitis","sequence":"additional","affiliation":[{"name":"Center of Radiation Oncology, National Cancer Center , Vilnius , Lithuania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2108-0241","authenticated-orcid":false,"given":"Mindaugas","family":"Dziugelis","sequence":"additional","affiliation":[{"name":"Center of Radiation Oncology, National Cancer Center , Vilnius , Lithuania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2055-8553","authenticated-orcid":false,"given":"Marius","family":"Burkanas","sequence":"additional","affiliation":[{"name":"Center of Radiation Oncology, National Cancer Center , Vilnius , Lithuania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9294-3190","authenticated-orcid":false,"given":"Jonas","family":"Venius","sequence":"additional","affiliation":[{"name":"Center of Radiation Oncology, National Cancer Center , Vilnius , Lithuania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8365-543X","authenticated-orcid":false,"given":"Giedre","family":"Smailyte","sequence":"additional","affiliation":[{"name":"Laboratory of Cancer Epidemiology , National Cancer Institute , Vilnius , Lithuania"},{"name":"Department of Public Health , Institute of Health Sciences, Faculty of Medicine, Vilnius University , Vilnius , Lithuania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2824-9110","authenticated-orcid":false,"given":"Marius","family":"Kincius","sequence":"additional","affiliation":[{"name":"Department of Oncourology , National Cancer Center , Vilnius , Lithuania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"key":"2026072008573626352_j_med-2026-1450_ref_001","doi-asserted-by":"crossref","unstructured":"Filho, AM, Laversanne, M, Ferlay, J, Colombet, M, Pi\u00f1eros, M, Znaor, A, et al.. The GLOBOCAN 2022 cancer estimates: data sources, methods, and a snapshot of the cancer burden worldwide. Int J Cancer 2025;156:1336\u201346. https:\/\/doi.org\/10.1002\/ijc.35278.","DOI":"10.1002\/ijc.35278"},{"key":"2026072008573626352_j_med-2026-1450_ref_002","doi-asserted-by":"crossref","unstructured":"Patasius, A, Krilaviciute, A, Smailyte, G. Prostate cancer screening with PSA: ten years\u2019 experience of population based early prostate cancer detection programme in Lithuania. J\u00a0Clin Med 2020;9:3826. https:\/\/doi.org\/10.3390\/jcm9123826.","DOI":"10.3390\/jcm9123826"},{"key":"2026072008573626352_j_med-2026-1450_ref_003","doi-asserted-by":"crossref","unstructured":"Pak, S, You, D, Jeong, IG, Lee, DE, Kim, SH, Joung, JY, et al.. Cause of mortality after radical prostatectomy and the impact of comorbidity in men with prostate cancer: a multi-institutional study in Korea. Cancer Res Treat 2020;52:1242\u201350. https:\/\/doi.org\/10.4143\/crt.2020.286.","DOI":"10.4143\/crt.2020.286"},{"key":"2026072008573626352_j_med-2026-1450_ref_004","doi-asserted-by":"crossref","unstructured":"Daskivich, TJ, Luu, M, Heard, J, Thomas, IC, Leppert, JT. Overtreatment of prostate cancer among men with limited longevity in the active surveillance era. JAMA Intern Med 2025;185:28\u201336. https:\/\/doi.org\/10.1001\/jamainternmed.2024.5994.","DOI":"10.1001\/jamainternmed.2024.5994"},{"key":"2026072008573626352_j_med-2026-1450_ref_005","doi-asserted-by":"crossref","unstructured":"Vickers, A, Vertosick, E, Langsetmo, L, Dahm, P, Steineck, G, Wilt, TJ. Estimating the effect of radical prostatectomy: combining data from the SPCG4 and PIVOT randomized trials with contemporary cohorts. J\u00a0Urol 2024;212:310\u20139. https:\/\/doi.org\/10.1097\/ju.0000000000004039.","DOI":"10.1097\/JU.0000000000004039"},{"key":"2026072008573626352_j_med-2026-1450_ref_006","doi-asserted-by":"crossref","unstructured":"Davis, MJ, Stephens, A, Abdollah, F. Fifteen-year outcomes of the ProtecT trial for localized prostate cancer. N\u00a0Engl J Med 2023;389:90\u20132.","DOI":"10.1056\/NEJMc2306135"},{"key":"2026072008573626352_j_med-2026-1450_ref_007","doi-asserted-by":"crossref","unstructured":"Aoun, F, Mjaess, G, Abi Tayeh, G, Sarkis, J, Lilly, E, Khalil, N, et al.. Focal therapy for prostate cancer: making the punishment fit the crime. Prog Urol 2021;31:1080\u20139. https:\/\/doi.org\/10.1016\/j.purol.2021.08.037.","DOI":"10.1016\/j.purol.2021.08.037"},{"key":"2026072008573626352_j_med-2026-1450_ref_008","doi-asserted-by":"crossref","unstructured":"Mohamad, O, Nicosia, L, Mathier, E, Riggenbach, E, Zamboglou, C, Aebersold, DM, et al.. Focal brachytherapy as definitive treatment for localized prostate cancer: a systematic review and meta-analysis. Brachytherapy 2024;23:309\u201320. https:\/\/doi.org\/10.1016\/j.brachy.2024.01.011.","DOI":"10.1016\/j.brachy.2024.01.011"},{"key":"2026072008573626352_j_med-2026-1450_ref_009","doi-asserted-by":"crossref","unstructured":"Guti\u00e9rrez-Valencia, E, Navarro-Domenech, I, Zhou, K, Barcelona, M, Fazelzad, R, Ramotar, M, et al.. Partial or focal brachytherapy for prostate cancer: a systematic review and meta-analysis. Br J Radiol 2025;98:354\u201367. https:\/\/doi.org\/10.1093\/bjr\/tqae254.","DOI":"10.1093\/bjr\/tqae254"},{"key":"2026072008573626352_j_med-2026-1450_ref_010","doi-asserted-by":"crossref","unstructured":"Peters, M, van Son, MJ, Moerland, MA, Kerkmeijer, LGW, Eppinga, WSC, Meijer, RP, et al.. MRI-guided ultrafocal HDR brachytherapy for localized prostate cancer: median 4-year results of a feasibility study. Int J Radiat Oncol Biol Phys 2019;104:1045\u201353. https:\/\/doi.org\/10.1016\/j.ijrobp.2019.03.032.","DOI":"10.1016\/j.ijrobp.2019.03.032"},{"key":"2026072008573626352_j_med-2026-1450_ref_011","doi-asserted-by":"crossref","unstructured":"Prada, PJ, Cardenal, J, Garc\u00eda Blanco, A, Andreescu, J, Ferri, M, Anchuelo, J, et al.. Focal high-dose-rate brachytherapy for localized prostate cancer: toxicity and preliminary biochemical results. Strahlenther Onkol 2020;196:222\u20138. https:\/\/doi.org\/10.1007\/s00066-019-01561-3.","DOI":"10.1007\/s00066-019-01561-3"},{"key":"2026072008573626352_j_med-2026-1450_ref_012","doi-asserted-by":"crossref","unstructured":"Hass, P, Fischbach, F, Pech, M, Gawish, A. Feasibility of MRI targeted single fraction HDR brachytherapy for localized prostate carcinoma: ProFocAL-study. J\u00a0Cancer Res Clin Oncol 2023;149:5397\u2013404. https:\/\/doi.org\/10.1007\/s00432-022-04491-3.","DOI":"10.1007\/s00432-022-04491-3"},{"key":"2026072008573626352_j_med-2026-1450_ref_013","doi-asserted-by":"crossref","unstructured":"Anderson, E, Smyth, LML, O\u2019Sullivan, R, Ryan, A, Lawrentschuk, N, Grummet, J, et al.. Focal low dose-rate brachytherapy for low to intermediate risk prostate cancer: preliminary experience at an Australian institution. Transl Androl Urol 2021;10:3591\u2013603. https:\/\/doi.org\/10.21037\/tau-21-508.","DOI":"10.21037\/tau-21-508"},{"key":"2026072008573626352_j_med-2026-1450_ref_014","doi-asserted-by":"crossref","unstructured":"Kunogi, H, Wakumoto, Y, Kawamoto, T, Oshima, M, Horie, S, Sasai, K. Focal low-dose-rate prostate brachytherapy for low- and intermediate-risk prostate cancer. J\u00a0Contemp Brachytherapy 2020;12:554\u201361. https:\/\/doi.org\/10.5114\/jcb.2020.101688.","DOI":"10.5114\/jcb.2020.101688"},{"key":"2026072008573626352_j_med-2026-1450_ref_015","doi-asserted-by":"crossref","unstructured":"Langley, S, Uribe, J, Uribe-Lewis, S, Mehta, S, Mikropoulos, C, Perna, C, et al.. Is hemi-gland focal LDR brachytherapy as effective as whole-gland treatment for unilateral prostate cancer? Brachytherapy 2022;21:870\u20136. https:\/\/doi.org\/10.1016\/j.brachy.2022.08.013.","DOI":"10.1016\/j.brachy.2022.08.013"},{"key":"2026072008573626352_j_med-2026-1450_ref_016","doi-asserted-by":"crossref","unstructured":"Graff, P, Portalez, D, Lusque, A, Brun, T, Aziza, R, Khalifa, J, et al.. IDEAL 2a phase II study of ultrafocal brachytherapy for low- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys 2018;102:903\u201311. https:\/\/doi.org\/10.1016\/j.ijrobp.2018.01.066.","DOI":"10.1016\/j.ijrobp.2018.01.066"},{"key":"2026072008573626352_j_med-2026-1450_ref_017","doi-asserted-by":"crossref","unstructured":"Jonu\u0161as, J, Patasius, A, Trakymas, M, Venius, J, Janulionis, E, Smailyte, G, et al.. Efficacy of focal high-dose-rate brachytherapy in the treatment of patients diagnosed with low or favourable: intermediate-risk prostate cancer-a protocol for a randomised controlled trial. BMJ Open 2023;13:e070020. https:\/\/doi.org\/10.1136\/bmjopen-2022-070020.","DOI":"10.1136\/bmjopen-2022-070020"},{"key":"2026072008573626352_j_med-2026-1450_ref_018","doi-asserted-by":"crossref","unstructured":"Maenhout, M, Peters, M, Moerland, MA, Meijer, RP, van den Bosch, MAAJ, Frank, SJ, et al.. MRI guided focal HDR brachytherapy for localized prostate cancer: toxicity, biochemical outcome and quality of life. Radiother Oncol 2018;129:554\u201360. https:\/\/doi.org\/10.1016\/j.radonc.2018.07.019.","DOI":"10.1016\/j.radonc.2018.07.019"},{"key":"2026072008573626352_j_med-2026-1450_ref_019","doi-asserted-by":"crossref","unstructured":"Wade, J, Donovan, J, Lane, A, Davis, M, Walsh, E, Neal, D, et al.. Strategies adopted by men to deal with uncertainty and anxiety when following an active surveillance\/monitoring protocol for localised prostate cancer and implications for care: a longitudinal qualitative study embedded within the ProtecT trial. BMJ Open 2020;10:e036024. https:\/\/doi.org\/10.1136\/bmjopen-2019-036024.","DOI":"10.1136\/bmjopen-2019-036024"},{"key":"2026072008573626352_j_med-2026-1450_ref_020","doi-asserted-by":"crossref","unstructured":"Kinsella, N, Stattin, P, Cahill, D, Brown, C, Bill-Axelson, A, Bratt, O, et al.. Factors influencing men\u2019s choice of and adherence to active surveillance for low-risk prostate cancer: a mixed-method systematic review. Eur Urol 2018;74:261\u201380. https:\/\/doi.org\/10.1016\/j.eururo.2018.02.026.","DOI":"10.1016\/j.eururo.2018.02.026"},{"key":"2026072008573626352_j_med-2026-1450_ref_021","doi-asserted-by":"crossref","unstructured":"Ta, MH, Nunes-Silva, I, Barret, E, Renard-Penna, R, Rozet, F, Mombet, A, et al.. Focal brachytherapy for localized prostate cancer: midterm outcomes. Pract Radiat Oncol 2021;11:e477\u201385. https:\/\/doi.org\/10.1016\/j.prro.2020.12.005.","DOI":"10.1016\/j.prro.2020.12.005"},{"key":"2026072008573626352_j_med-2026-1450_ref_022","doi-asserted-by":"crossref","unstructured":"Pinkawa, M, Asadpour, B, Gagel, B, Piroth, MD, Borchers, H, Jakse, G, et al.. Evaluation of source displacement and dose--volume changes after permanent prostate brachytherapy with stranded seeds. Radiother Oncol 2007;84:190\u20136. https:\/\/doi.org\/10.1016\/j.radonc.2007.07.014.","DOI":"10.1016\/j.radonc.2007.07.014"},{"key":"2026072008573626352_j_med-2026-1450_ref_023","doi-asserted-by":"crossref","unstructured":"Moerland, MA, van Deursen, MJH, Elias, SG, van Vulpen, M, J\u00fcrgenliemk-Schulz, IM, Battermann, JJ. Decline of dose coverage between intraoperative planning and post implant dosimetry for I-125 permanent prostate brachytherapy: comparison between\u00a0loose and stranded seed implants. Radiother Oncol 2009;91:202\u20136. https:\/\/doi.org\/10.1016\/j.radonc.2008.09.013.","DOI":"10.1016\/j.radonc.2008.09.013"},{"key":"2026072008573626352_j_med-2026-1450_ref_024","doi-asserted-by":"crossref","unstructured":"Corkum, M, Loblaw, A, Hasan, Y, Chung, HT, Tseng, CL, McGuffin, M, et al.. Prostate high dose-rate brachytherapy as monotherapy for prostate cancer: late toxicity and patient reported outcomes from a randomized phase II clinical trial. Radiother Oncol 2021;156:160\u20135. https:\/\/doi.org\/10.1016\/j.radonc.2020.12.021.","DOI":"10.1016\/j.radonc.2020.12.021"},{"key":"2026072008573626352_j_med-2026-1450_ref_025","doi-asserted-by":"crossref","unstructured":"Martinez, AA, Demanes, J, Vargas, C, Schour, L, Ghilezan, M, Gustafson, GS. High-dose-rate prostate brachytherapy: an excellent accelerated-hypofractionated treatment for favorable prostate cancer. Am J Clin Oncol 2010;33:481\u20138. https:\/\/doi.org\/10.1097\/coc.0b013e3181b9cd2f.","DOI":"10.1097\/COC.0b013e3181b9cd2f"},{"key":"2026072008573626352_j_med-2026-1450_ref_026","doi-asserted-by":"crossref","unstructured":"Guinot, JL, Casanova, J, Gonzalez-Perez, V, Santos, MA, De Los Dolores, V, Tortajada, MI, et al.. Long-term results with custom-linked iodine-125 seeds and real-time brachytherapy in low- and intermediate-risk prostate cancer. J\u00a0Contemp Brachytherapy 2022;14:215\u201321. https:\/\/doi.org\/10.5114\/jcb.2022.116150.","DOI":"10.5114\/jcb.2022.116150"},{"key":"2026072008573626352_j_med-2026-1450_ref_027","doi-asserted-by":"crossref","unstructured":"Hudson, JM, Loblaw, A, McGuffin, M, Chung, HT, Tseng, CL, Helou, J, et al.. Prostate high dose-rate brachytherapy as monotherapy for low and intermediate-risk prostate cancer: efficacy results from a randomized phase II clinical trial of one fraction of 19\u00a0Gy or two fractions of 13.5 Gy: a 9-year update. Radiother Oncol 2024;198:110381.","DOI":"10.1016\/j.radonc.2024.110381"},{"key":"2026072008573626352_j_med-2026-1450_ref_028","doi-asserted-by":"crossref","unstructured":"Andreoiu, M, Cheng, L. Multifocal prostate cancer: biologic, prognostic, and therapeutic implications. Hum Pathol 2010;41:781\u201393. https:\/\/doi.org\/10.1016\/j.humpath.2010.02.011.","DOI":"10.1016\/j.humpath.2010.02.011"},{"key":"2026072008573626352_j_med-2026-1450_ref_029","doi-asserted-by":"crossref","unstructured":"Aihara, M, Wheeler, TM, Ohori, M, Scardino, PT. Heterogeneity of prostate cancer in radical prostatectomy specimens. Urology 1994;43:60\u20136. https:\/\/doi.org\/10.1016\/s0090-4295(94)80264-5.","DOI":"10.1016\/S0090-4295(94)80264-5"},{"key":"2026072008573626352_j_med-2026-1450_ref_030","doi-asserted-by":"crossref","unstructured":"Borren, A, Groenendaal, G, Moman, MR, Boeken Kruger, AE, van Diest, PJ, van Vulpen, M, et al.. Accurate prostate tumour detection with multi-parametric magnetic resonance imaging: dependence on histological properties. Acta Oncol 2014;53:88\u201395. https:\/\/doi.org\/10.3109\/0284186x.2013.837581.","DOI":"10.3109\/0284186X.2013.837581"},{"key":"2026072008573626352_j_med-2026-1450_ref_031","doi-asserted-by":"crossref","unstructured":"Huang, CC, Deng, FM, Kong, MX, Ren, Q, Melamed, J, Zhou, M. Re-evaluating the concept of \u201cdominant\/index tumor nodule\u201d in multifocal prostate cancer. Virchows Arch 2014;464:589\u201394. https:\/\/doi.org\/10.1007\/s00428-014-1557-y.","DOI":"10.1007\/s00428-014-1557-y"}],"container-title":["Open Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/med-2026-1450\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/med-2026-1450\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T08:57:52Z","timestamp":1784537872000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/med-2026-1450\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,1]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,7,20]]},"published-print":{"date-parts":[[2026,1,23]]}},"alternative-id":["10.1515\/med-2026-1450"],"URL":"https:\/\/doi.org\/10.1515\/med-2026-1450","relation":{},"ISSN":["2391-5463"],"issn-type":[{"value":"2391-5463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,1]]},"article-number":"20261450"}}